{"ctNumber":"2024-515163-63-00","ctStatus":"Authorised","decisionDate":"2025-06-18T14:40:15.712","publishDate":"2026-08-28T03:39:47.04373319","ctPublicStatusCode":2,"authorizedApplication":{"authorizedPartI":{"id":136835,"rowSubjectCount":0,"products":[{"id":569476,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"12057625","productPharmForm":"CAPSULE","euMpNumber":"PRD12057625","prodAuthStatus":1,"pharmForm":"CAPSULE","sponsorProductCode":"PEX010","activeSubstanceName":"DRY EXTRACT FROM PSILOCYBE CUBENSIS (15-25:1), EXTRACTION SOLVENT: METHANOL","euSubstNumber":"SUB267722","nameOrg":"REGION SKANE","productSubstances":[{"productPk":"12057625","substancePk":"377754","nameOrg":"REGION SKANE","substanceOrigin":"Specified Substance Group 1","actSubstOrigin":"Specified Substance Group 1","actSubstName":"DRY EXTRACT FROM PSILOCYBE CUBENSIS (15-25:1), EXTRACTION SOLVENT: METHANOL","substanceEvCode":"SUB267722"}],"activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"25","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"50","maxTreatmentPeriod":2,"timeUnitCode":"1","evCode":"PRD12057625","sponsorProductCodeEdit":"PEX010","devices":[],"characteristics":["2"],"routes":["ORAL USE"],"allSubstancesChemicals":false,"jsonActiveSubstanceNames":"dry extract from psilocybe cubensis (15-25:1), extraction solvent: methanol","pharmaceuticalFormDisplay":"CAPSULE"}],"trialDetails":{"clinicalTrialIdentifiers":{"fullTitle":"The therapeutic potential of psilocybin in anorexia nervosa in young adults","fullTitleTranslations":[],"publicTitle":"The therapeutic potential of psilocybin in anorexia nervosa in young adults","publicTitleTranslations":[],"secondaryIdentifyingNumbers":{"additionalRegistries":[]}},"trialInformation":{"trialCategory":{"isLowIntervention":false,"trialPhase":"4","trialCategory":"2","justificationForTrialCategory":"This clinical trial phase II study involves administering an investigational medicinal product (psilocybin) to assess its safety, tolerability, and efficacy in patients with severe anorexia nervosa.","trialCategoryId":126298},"medicalCondition":{"partIMedicalConditions":[{"id":143147,"medicalCondition":"Anorexia Nervosa","medicalConditionTranslations":[],"isConditionRareDisease":false}],"meddraConditionTerms":[{"termId":100000019467,"version":"20.0","level":"PT","termName":"Anorexia nervosa","classificationCode":"10002649","organClass":100000004873,"active":false}]},"trialObjective":{"trialScopes":[{"code":"5","trialScopeId":415579},{"code":"4","trialScopeId":415581},{"code":"3","trialScopeId":415580}],"mainObjective":"To evaluate the safety and tolerability of two doses of psilocybin (25 mg) one month apart, administered with psychological support in young adults (16-35 years) with anorexia nervosa (AN) compared to the standard Treatment as Usual (TAU).","mainObjectiveTranslations":[],"secondaryObjectives":[{"id":487885,"number":1,"secondaryObjective":"Mechanisms of action of psilocybin through neurobiological assessments and neuroimaging","secondaryObjectiveTranslations":[]},{"id":487886,"number":2,"secondaryObjective":"Qualitative analysis of the subjective experiences of the intervention by patients, relatives, and therapists.","secondaryObjectiveTranslations":[]},{"id":487887,"number":3,"secondaryObjective":"Time to relapse, response and remission.","secondaryObjectiveTranslations":[]},{"id":487888,"number":4,"secondaryObjective":"Changes in psychological self-report measurements.","secondaryObjectiveTranslations":[]}]},"eligibilityCriteria":{"principalInclusionCriteria":[{"id":929832,"number":1,"principalInclusionCriteria":"Anorexia Nervosa as defined by DSM-5.","principalInclusionCriteriaTranslations":[]},{"id":929833,"number":2,"principalInclusionCriteria":"Age 16-35","principalInclusionCriteriaTranslations":[]},{"id":929834,"number":3,"principalInclusionCriteria":"Ongoing stable contact with an outpatient psychiatric unit.","principalInclusionCriteriaTranslations":[]},{"id":929835,"number":4,"principalInclusionCriteria":"BMI >16.","principalInclusionCriteriaTranslations":[]},{"id":929836,"number":5,"principalInclusionCriteria":"Have experienced at least one period of remission (minimum BMI 17) followed by a relapse.","principalInclusionCriteriaTranslations":[]}],"principalExclusionCriteria":[{"id":1589287,"number":1,"principalExclusionCriteria":"Psychosis, bipolar disorder or substance use disorder","principalExclusionCriteriaTranslations":[]},{"id":1589288,"number":10,"principalExclusionCriteria":"Positive drug tests","principalExclusionCriteriaTranslations":[]},{"id":1589289,"number":11,"principalExclusionCriteria":"Suicidal intent.","principalExclusionCriteriaTranslations":[]},{"id":1589290,"number":12,"principalExclusionCriteria":"Allergy or intolerance to drug content.","principalExclusionCriteriaTranslations":[]},{"id":1589291,"number":13,"principalExclusionCriteria":"Any other clinically significant medical condition that, in the investigator’s opinion, may pose a risk to the participant or interfere with study results.","principalExclusionCriteriaTranslations":[]},{"id":1589292,"number":2,"principalExclusionCriteria":"Blood or needle phobia.","principalExclusionCriteriaTranslations":[]},{"id":1589293,"number":3,"principalExclusionCriteria":"Unable to follow study protocol.","principalExclusionCriteriaTranslations":[]},{"id":1589294,"number":4,"principalExclusionCriteria":"Presence of metal pieces in the body (contraindicated by fMRI).","principalExclusionCriteriaTranslations":[]},{"id":1589295,"number":5,"principalExclusionCriteria":"Family history of psychosis or bipolar disorder.","principalExclusionCriteriaTranslations":[]},{"id":1589296,"number":6,"principalExclusionCriteria":"Refusal of birth control during until primary endpoint.","principalExclusionCriteriaTranslations":[]},{"id":1589297,"number":7,"principalExclusionCriteria":"Previous use of classical psychedelics","principalExclusionCriteriaTranslations":[]},{"id":1589298,"number":8,"principalExclusionCriteria":"Ongoing medications that would interfere negatively with the study drug.","principalExclusionCriteriaTranslations":[]},{"id":1589299,"number":9,"principalExclusionCriteria":"Cardiovascular conditions, epilepsy, diabetes mellitus","principalExclusionCriteriaTranslations":[]}]},"endPoint":{"primaryEndPoints":[{"id":1086494,"number":1,"endPoint":"Incidence of adverse events (AEs) and serious adverse events (SAEs) during the trial period.","isPrimary":true,"endPointTranslations":[]}],"secondaryEndPoints":[{"id":1086495,"number":1,"endPoint":"General Anxiety (GAD-2)","isPrimary":false,"endPointTranslations":[]},{"id":1086496,"number":2,"endPoint":"Patient Health Questionnaire (PHQ-2)","isPrimary":false,"endPointTranslations":[]},{"id":1086497,"number":3,"endPoint":"Experiences in Close Relationships – (ECR–RS)","isPrimary":false,"endPointTranslations":[]},{"id":1086498,"number":4,"endPoint":"Life Satisfaction (LS)","isPrimary":false,"endPointTranslations":[]},{"id":1086499,"number":5,"endPoint":"Positive & Neg Affect  (PANAS)","isPrimary":false,"endPointTranslations":[]},{"id":1086500,"number":6,"endPoint":"Harmony in Life (HILS)","isPrimary":false,"endPointTranslations":[]},{"id":1086501,"number":7,"endPoint":"Self-compassion (Short SCS)","isPrimary":false,"endPointTranslations":[]},{"id":1086502,"number":8,"endPoint":"Ten Item Pers Inv (TIPI)","isPrimary":false,"endPointTranslations":[]},{"id":1086503,"number":9,"endPoint":"AN symptom severity (EDE)","isPrimary":false,"endPointTranslations":[]},{"id":1086504,"number":10,"endPoint":"Response: A clinically significant improvement in weight and psychological symptoms during the treatment period.","isPrimary":false,"endPointTranslations":[]},{"id":1086505,"number":11,"endPoint":"Remission: The achievement and maintenance of weight restoration and psychological well-being, with no significant symptoms of anorexia nervosa.","isPrimary":false,"endPointTranslations":[]},{"id":1086506,"number":12,"endPoint":"Relapse: Defined as a composite outcome during the 6-month follow-up period","isPrimary":false,"endPointTranslations":[]}]},"trialDuration":{"estimatedEndDate":"2026-12-31","estimatedRecruitmentStartDate":"2025-04-01"},"sourceOfMonetarySupport":[{"id":100568,"organisationName":"Norrsken MIND"}],"populationOfTrialSubjects":{"ageRanges":[{"id":376010,"ageRangeCategoryCode":"2","ageRangeCategory":"2"},{"id":376011,"ageRangeCategoryCode":"3","ageRangeCategory":"3"}],"ageRangeSecondaryIds":[],"clinicalTrialGroups":[{"code":"2","name":"Patients"}],"isFemaleSubjects":true,"isMaleSubjects":true,"isVulnerablePopulationSelected":false},"individualParticipantData":{"planToShareIPD":"1","planDescription":"Will individual participant data (IPD) be shared?\nYes.\n\nWhat data will be shared?\nDe-identified baseline characteristics, primary and secondary outcomes, and supporting documents like the study protocol and analysis plan.\n\nWhen will data be available?\nWithin 12 months following the publication of primary results.\n\nFor how long?\nAt least 5 years post-publication.\n\nTo whom?\nResearchers from accredited institutions with a methodologically sound proposal aimed at understanding anorexia nervosa or psychedelic therapies.\n\nFor what types of analyses?\nMeta-analyses, systematic reviews, and replication studies.\n\nHow will data be shared?\nVia a secure repository at Lund University after approval by a Data Access Committee and signing a data-sharing agreement."}},"protocolInformation":{"studyDesign":{"periodDetails":[]}},"scientificAdviceAndPip":{"scientificAdvices":[],"paediatricInvestigationPlan":[]},"associatedClinicalTrials":[],"references":[],"pubmedCode":[],"pubmedUrl":[]},"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-08-14","conclusionDate":"2026-08-14","therapeuticAreas":[{"code":"32","name":"Psychiatry and Psychology [F] - Psychological Phenomena [F02]"},{"code":"31","name":"Psychiatry and Psychology [F] - Behavior and Behavior Mechanisms [F01]"},{"code":"33","name":"Psychiatry and Psychology [F] - Mental Disorders [F03]"}],"medicalConditions":[{"id":143147,"medicalCondition":"Anorexia Nervosa","isConditionRareDisease":false}],"sponsors":[{"id":155669,"primary":true,"publicContacts":[{"id":459500,"type":"Public","functionalName":"Pouya Movahed Rad","functionalEmailAddress":"pouya.movahed_rad@med.lu.se","telephone":"+46178825","organisation":{"id":507838,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Region Skane","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100039964","organisationLocationStatus":"Active"}}],"scientificContacts":[{"id":459501,"type":"Scientific","functionalName":"Pouya Movahed Rad","functionalEmailAddress":"pouya.movahed_rad@med.lu.se","telephone":"+46178825","organisation":{"id":507838,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Region Skane","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100039964","organisationLocationStatus":"Active"}}],"thirdParties":[],"organisation":{"id":507838,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Region Skane","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100039964","organisationLocationStatus":"Active"},"addresses":[{"id":475451,"organisation":{"id":507838,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Region Skane","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100039964","organisationLocationStatus":"Active"},"address":{"addressId":509875,"oneLine":"Dockplatsen 26, Malmo S:t Petri","addressLine1":"Dockplatsen 26","addressLine2":"Malmo S:t Petri","addressLine3":"","addressLine4":"","city":"Malmo","postcode":"211 74","country":2028,"countryName":"Sweden"},"isBusinessKeyValidated":true,"businessKey":"ORG-100039964"}],"isCommercial":false,"commercial":"Non-Commercial"}],"trialCategoryCode":"2","trialCategoryJustificationComment":"This clinical trial phase II study involves administering an investigational medicinal product (psilocybin) to assess its safety, tolerability, and efficacy in patients with severe anorexia nervosa.","partOneTherapeuticAreas":[{"id":1200834,"therapeuticArea":{"code":"32","name":"Psychiatry and Psychology [F] - Psychological Phenomena [F02]"}},{"id":1200833,"therapeuticArea":{"code":"31","name":"Psychiatry and Psychology [F] - Behavior and Behavior Mechanisms [F01]"}},{"id":1200835,"therapeuticArea":{"code":"33","name":"Psychiatry and Psychology [F] - Mental Disorders [F03]"}}],"productRoleGroupInfos":[{"id":423687,"comments":"null","productRoleCode":"1","productRoleName":"Test","products":[{"id":569476,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"12057625","productPharmForm":"CAPSULE","euMpNumber":"PRD12057625","prodAuthStatus":1,"pharmForm":"CAPSULE","sponsorProductCode":"PEX010","activeSubstanceName":"DRY EXTRACT FROM PSILOCYBE CUBENSIS (15-25:1), EXTRACTION SOLVENT: METHANOL","euSubstNumber":"SUB267722","nameOrg":"REGION SKANE","productSubstances":[{"productPk":"12057625","substancePk":"377754","nameOrg":"REGION SKANE","substanceOrigin":"Specified Substance Group 1","actSubstOrigin":"Specified Substance Group 1","actSubstName":"DRY EXTRACT FROM PSILOCYBE CUBENSIS (15-25:1), EXTRACTION SOLVENT: METHANOL","substanceEvCode":"SUB267722"}],"activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"25","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"50","maxTreatmentPeriod":2,"timeUnitCode":"1","evCode":"PRD12057625","sponsorProductCodeEdit":"PEX010","devices":[],"characteristics":["2"],"routes":["ORAL USE"],"allSubstancesChemicals":false,"jsonActiveSubstanceNames":"dry extract from psilocybe cubensis (15-25:1), extraction solvent: methanol","pharmaceuticalFormDisplay":"CAPSULE"}]}],"isLowIntervention":false},"authorizedPartsII":[{"id":333543,"mscId":34559,"mscInfo":{"id":34559,"clinicalTrialId":16082,"countryOrganisationId":2028,"reportingStatusCode":"Authorised","fromDate":"2025-06-01","toDate":"2025-06-01","isProposedRms":true,"countryName":"Sweden","organisationInfo":{},"firstDecisionDate":"2025-06-18","trialStatus":"Authorised","trialPeriod":[],"trialRecruitmentPeriod":[],"hasRecruitmentStarted":false,"activeTrialPeriod":{},"activeTrialRecruitmentPeriod":{},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":79032,"mscId":34559,"trialStatus":"Under evaluation","trialStatusDate":"2025-03-21T13:44:00.214"},{"id":85582,"mscId":34559,"trialStatus":"Authorised","trialStatusDate":"2025-06-18T14:40:15.344"}],"applicationTypeMsc":"1","mscName":"Sweden","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-08-27","decision":"authorized","decisionDate":"2025-06-18"},"decisionDate":"2025-06-18","recruitmentSubjectCount":40,"trialSites":[{"id":2343159,"organisationAddressInfo":{"id":529836,"organisation":{"id":562410,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Region Skane Skanes Universitetssjukhus","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100011290","organisationLocationStatus":"Active"},"address":{"addressId":569696,"oneLine":"Halsogatan 3, Lunds Allhelgonafors.","addressLine1":"Halsogatan 3","addressLine2":"Lunds Allhelgonafors.","addressLine3":"","addressLine4":"","city":"Lund","postcode":"222 42","country":2028,"countryName":"Sweden"},"phone":"+46705729613","email":"pouya.movahed_rad@med.lu.se","isBusinessKeyValidated":true,"businessKey":"ORG-100011290"},"personInfo":{"id":2597191,"firstName":"Pouya","lastName":"Movahed Rad","telephone":"+46705729613","email":"pouya.movahed_rad@med.lu.se","title":"1"},"departmentName":"Vuxenpsykiatri Lund, Baravägen 1, 221 85 Lund"}],"applicationStatusCode":"Authorised"}],"applicationInfo":[{"id":27798,"type":"INITIAL","status":"Authorised","ctNumber":"2024-515163-63-00","trialStatus":"Authorised","submissionDate":"2025-03-21","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-06-18"},"partIIInfo":[{"id":213272,"mscId":34559,"mscInfo":{"id":34559,"mscName":"Sweden","countryOrganisationId":2028,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-06-10","decision":"authorized","decisionDate":"2025-06-18","reportingStatusCode":"Authorised","countryName":"Sweden","trialStatus":"Authorised","firstDecisionDate":"2025-06-18"},"applicationStatusCode":"Authorised"}],"decisionDate":"2025-06-18","ctMSCsByApplication":[{"id":34559,"mscName":"Sweden","reportingStatusCode":"Authorised"}],"businessKey":"IN","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":76524,"applicationId":27798,"mscId":34559,"mscName":"Sweden","decisionDate":"2025-06-18T14:40:15.712","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":213272,"part1Id":87684,"applicationType":"INITIAL","isRMS":true}]},{"id":72386,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2024-515163-63-00","trialStatus":"Authorised","submissionDate":"2025-12-09","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-02-04"},"partIIInfo":[{"id":265372,"mscId":34559,"mscInfo":{"id":34559,"mscName":"Sweden","countryOrganisationId":2028,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-02-11","decision":"authorized","decisionDate":"2025-06-18","reportingStatusCode":"Authorised","countryName":"Sweden","trialStatus":"Authorised","firstDecisionDate":"2025-06-18"},"applicationStatusCode":"Authorised"}],"decisionDate":"2026-02-11","ctMSCsByApplication":[{"id":34559,"mscName":"Sweden","reportingStatusCode":"Authorised"}],"businessKey":"SM-2","modScope":"PART_I_AND_PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":109284,"applicationId":72386,"mscId":34559,"mscName":"Sweden","decisionDate":"2026-02-11T14:15:18.574","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":265372,"part1Id":111192,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true}]},{"id":79275,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2024-515163-63-00","trialStatus":"Authorised","submissionDate":"2026-03-11","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-04-16"},"partIIInfo":[{"id":287721,"mscId":34559,"mscInfo":{"id":34559,"mscName":"Sweden","countryOrganisationId":2028,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-03-26","decision":"authorized","decisionDate":"2025-06-18","reportingStatusCode":"Authorised","countryName":"Sweden","trialStatus":"Authorised","firstDecisionDate":"2025-06-18"},"applicationStatusCode":"Authorised"}],"decisionDate":"2026-04-17","ctMSCsByApplication":[{"id":34559,"mscName":"Sweden","reportingStatusCode":"Authorised"}],"businessKey":"SM-3","modScope":"PART_I_AND_PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":119572,"applicationId":79275,"mscId":34559,"mscName":"Sweden","decisionDate":"2026-04-17T11:53:34.083","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":287721,"part1Id":121437,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true}]},{"id":89686,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2024-515163-63-00","trialStatus":"Authorised","submissionDate":"2026-07-31","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-08-14"},"partIIInfo":[{"id":333543,"mscId":34559,"mscInfo":{"id":34559,"mscName":"Sweden","countryOrganisationId":2028,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-08-27","decision":"authorized","decisionDate":"2025-06-18","reportingStatusCode":"Authorised","countryName":"Sweden","trialStatus":"Authorised","firstDecisionDate":"2025-06-18"},"applicationStatusCode":"Authorised"}],"decisionDate":"2026-08-27","ctMSCsByApplication":[{"id":34559,"mscName":"Sweden","reportingStatusCode":"Authorised"}],"businessKey":"SM-4","modScope":"PART_I_AND_PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":139504,"applicationId":89686,"mscId":34559,"mscName":"Sweden","decisionDate":"2026-08-27T13:15:03.636","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":333543,"part1Id":136835,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true}]}],"trialGlobalEnd":[],"memberStatesConcerned":[{"mscName":"Sweden","mscId":34559,"firstDecisionDate":"2025-06-18T14:40:15.712","lastDecisionDate":"2026-08-27T13:15:03.636","mscPublicStatusCode":2}],"eudraCt":{"isTransitioned":false}},"events":{"temporaryHaltList":[],"trialEvents":[{"mscId":34559,"mscName":"Sweden","events":[]}],"unexpectedEvents":[],"seriousBreaches":[],"urgentSafetyMeasures":[]},"results":{},"documents":[{"title":"psiAN study protocol","uuid":"031ac920-221a-4ae0-b005-161d715119c4","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"DOCX","associatedEntityId":136835,"manualVersion":"10","systemVersion":"3"},{"title":"Schedule of Assessments","uuid":"2f7ec1fb-a181-47fd-bd08-bbdc55b2e59c","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"DOCX","associatedEntityId":136835,"manualVersion":"10","systemVersion":"2"},{"title":"Synopsis_SE","uuid":"4cb544f4-f453-4fde-8dd4-4fd6a59eeed5","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":6,"fileType":"DOCX","associatedEntityId":136835,"manualVersion":"2","systemVersion":"2"},{"title":"Annons psiAN","uuid":"d3859dde-20d4-40c8-94f8-71cb8ba80f60","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":24,"fileType":"PDF","associatedEntityId":333543,"manualVersion":"3","systemVersion":"2"},{"title":"psiAN- Recruitment and Consent Process250319","uuid":"e6755ca0-8eec-4680-aac0-2f1a9f2b9024","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":24,"fileType":"DOCX","associatedEntityId":333543,"manualVersion":"2","systemVersion":"1"},{"title":"Affisch fokusgrupper 251119","uuid":"bbc6abd9-8465-4b2c-9088-1077182efe52","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":24,"fileType":"PDF","associatedEntityId":333543,"manualVersion":"1","systemVersion":"1"},{"title":"V2 Annons fokusgrupper 251121","uuid":"29c3ab9c-da3e-4ba2-aa47-fd3445327cf8","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":24,"fileType":"PDF","associatedEntityId":333543,"manualVersion":"2","systemVersion":"1"},{"title":"Forskningspersonsinformation Informerat samtycke Deltagare","uuid":"814e8b8d-600a-42e8-b04b-cb0f3e3a29e7","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":24,"fileType":"DOCX","associatedEntityId":333543,"manualVersion":"10.1","systemVersion":"4"},{"title":"Fokusgrupper - FPI 251005v1","uuid":"db8149a8-73e8-4d91-8062-8d46da276f51","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":24,"fileType":"DOCX","associatedEntityId":333543,"manualVersion":"1","systemVersion":"1"},{"title":"Samtycke foksugrupper 251005","uuid":"156e4429-ca82-409a-9c18-01e5cd14c246","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":38,"fileType":"DOCX","associatedEntityId":333543,"manualVersion":"1","systemVersion":"1"},{"title":"Forskningspersonsinformation Informerat samtycke Vardnadshavare","uuid":"eb187e85-8d48-45f4-a8e9-21d3486a616c","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":24,"fileType":"DOCX","associatedEntityId":333543,"manualVersion":"10.1","systemVersion":"2"}],"trialRegion":"EEA","trialRegionCode":1,"correctiveMeasures":[]}